

TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED
STANDALONE ASSETS AND LIABILITIES FOR THE YEAR ENDED ON 31-03-2015

(Rupees in Lacs)

Particulars	As at 31/03/2015	As at 31/03/2014
A. EQUITY AND LIABILITIES		
1. Share Holders' Funds:		
(a) Share Capital	810.00	810.00
(b) Reserves and Surplus	324.27	334.84
(c) Money received against warrants	0.00	0.00
Sub-Total Share Holders' Funds	1134.27	1144.84
2. Share Application pending for Allotment	-Nil-	-Nil-
3. Minority Interest*	-Nil-	-Nil-
4. Non Current Liabilities:		
(a) Long Term Borrowings	-Nil-	1.36
(b) Deferred Tax Liabilities (Net)	8.27	11.60
(c) Other Long Term Liabilities	-Nil-	-Nil-
(d) Long Term Provisions	-Nil-	-Nil-
Sub-Total Non Current Liabilities	8.27	12.96
4. Current Liabilities		
(a) Short Term Borrowings	-Nil-	-Nil-
(b) Trade Payables	-Nil-	4.51
(c) Other Current Liabilities	7.48	10.70
(d) Short Term Provisions	10.24	21.46
(e) Inter Division	-Nil-	-Nil-
Sub-Total Current Liabilities	17.73	36.67
TOTAL EQUITY & LIABILITIES	1160.26	1194.47
B. ASSETS		
1. Non-Current Assets:		
(a) Fixed Assets	74.94	117.15
(b) Non-Current Investments	140.28	31.50
(c) Deferred Tax Assets (Net)	-Nil-	-Nil-
(d) Long Term Loans and Advances	20.52	20.52
(e) Other Non-Current Assets	-Nil-	-Nil-
Sub-Total Non Current Assets	235.73	169.17
2. Current Assets:		
(a) Current Investments	-Nil-	-Nil-
(b) Inventories	-Nil-	32.21
(c) Trade Receivables	11.83	84.72
(d) Cash & Cash Equivalents	17.48	86.95
(e) Short Term Loans and Advances	881.46	806.09
(f) Other Current Assets	13.75	15.33
Sub-Total Current Assets	924.53	1025.30
TOTAL ASSETS	1160.26	1194.47

Trimurthi Drugs & Pharmaceuticals Ltd.


Managing Director

Trimurthi Drugs & Pharmaceuticals Ltd.

4-4-231/1/2 ABC, Inder Bagh, Sultan Bazar,
Hyderabad - 500 095, A.P., India

0018056

TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED
STANDALONE AUDITED QUARTERLY RESULTS FOR THE QUARTER ENDED MARCH, 2015

PART-II

SELECT INFORMATION FOR QUARTER IV AND YEAR ENDED 31-03-2015

Particulars	3 Months ended 31-03-2015	Preceeding 3 months ended 30-12-2014	Corresponding 3 months ended 31-03-2014	Year to date figures for the current period ended 31-03-2015	Year ended 31-03-2014
	Audited	Unaudited	Audited	Audited	Audited
A. Particulars Of Share Holding					
1. Public Share Holding					
- Number of Shares	2849600	3102200	3366200	2849600	3166200
- Percentage of shareholding	35.18%	38.30%	41.56%	35.18%	39.09%
2. Promoters and promoter group shareholding					
a. Pledged / encumbered					
- No of Equity Shares	Nil	Nil	Nil	Nil	Nil
- Percentage of Shares (of the shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil
- Percentage of Shares (of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil
b. Non encumbered					
- No of Equity Shares	5250400	4997800	4733800	5250400	4933800
- Percentage of Shares (of the shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of Shares (of the total share capital of the company)	64.82%	61.70%	58.44%	64.82%	60.91%

Particulars	3 Months Ended (31/03/2015)
B. Investor Complaints	
Pending at the beginning of the quarter	-NIL-
Received during the quarter	-NIL-
Disposed during the quarter	-NIL-
Remaining unsolved during the quarter	-NIL-

Segment Reporting

Particulars	Quarters ended			Year Ended	Year ended
	31/03/2015	31/12/2014	31/03/2014	31/03/2015	31/03/2014
	Audited	Unaudited	Audited	Audited	Audited
1. Segment Revenue					
a. Pharma Business	0.00	0.00	133.27	31.40	486.39
b. Financial Services	30.76	30.83	19.83	114.23	89.48
c. Investments	(19.67)	0.00	0.00	(19.67)	0.01
d. Trading in Shares	0.00	0.00	0.00	0.00	0.00
Total	11.09	30.83	153.10	125.96	575.88
Less: Inter Segment Revenue	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
Net Sales/ Income From Operations	11.09	30.83	153.10	125.96	575.88
2. Segment Profits (Before tax & Interest From Each Segment)					
a. Pharma Business	(0.00)	0.00	(13.32)	(1.47)	(19.51)
b. Financial Services	(11.50)	16.85	16.36	30.81	80.44
c. Investments	(20.56)	0.00	0.00	(20.56)	0.01
d. Trading in Shares	0.00	0.00	0.00	0.00	0.00
Total	(32.07)	16.85	3.04	8.78	60.94
Less:					
i. Interest	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
ii. Other Un-allocable expenses net off	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
iii. Un-allocable Income	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
Total Profit Before Tax	(32.07)	16.85	3.04	8.78	60.94
3. Capital Employed					
a. Pharma Business	11.92	16.66	202.99	11.92	202.99

of Trimurthi Drugs & Pharmaceuticals Ltd

Trimurthi Drugs & Pharmaceuticals Ltd.

4-4-231/1/2 ABC, Inder Bagh, Sultan Bazar,
Hyderabad - 500 095, A.P., India

Managing Director

TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED
STANDALONE AUDITED QUARTERLY RESULTS FOR THE YEAR ENDED MARCH, 2015

PART-I					
STATEMENT OF STANDALONE AUDITED RESULTS FOR QUARTER IV AND YEAR ENDED 31-03-2015					
<i>(Rs. In Lakhs)</i>					
Particulars	3 Months ended 31-03-2015	Preceeding 3 months ended 31-12-2014	Corresponding 3 months ended 31-03-2014	Year to date figures for the current period ended 31-03-2015	Year ended 31-03-2014
	Audited	Unaudited	Audited	Audited	Audited
1. Income From Operations					
Net Sales / Income from Operations	0.00	0.00	139.63	31.40	484.75
Other Operating Income	30.76	30.83	13.47	114.23	91.13
Total Operating Income(Net)	30.76	30.83	153.10	145.63	575.88
2. Expenditure					
a. Consumption of Raw Material	Nil	Nil	Nil	Nil	
b. Purchase of Traded Goods/Shares	0.00	0.00	98.31	0.08	422.95
c. (Increase)/Decrease in stock in trade and work in Progress	0.00	0.00	20.71	32.21	1.07
d. Employees Cost	2.37	1.42	14.39	6.22	33.13
e. Depreciation	17.03	7.21	7.18	39.57	28.53
f. Other Expenditure	22.66	5.25	9.34	37.74	28.62
Total	42.06	13.87	149.93	115.83	514.30
Profit/ (Loss) from Operations before Other Income, Finance Cost & Exceptional Items (2-1)	(11.30)	16.96	3.17	29.80	61.58
4. Other Income	(20.63)			(20.63)	
Profit/ (Loss) from Ordinary Activities before Finance Cost & Exceptional Items (3+4)	(31.93)	16.96	3.17	9.17	61.58
6. Finance Cost	0.13	0.11	0.13	0.39	0.64
7. Profit/ (Loss) from Ordinary activities after finance cost but before exceptional items (5+6)	(32.07)	16.85	3.04	8.78	60.94
8. Exceptional Items	Nil	Nil	Nil	Nil	Nil
9. Profit/ (Loss) from Ordinary activities before tax (7+8)	(32.07)	16.85	3.04	8.78	60.94
10. Tax Expense (Including Deferred Tax)	(6.08)	5.21	(0.54)	6.92	19.36
11. Net Profit/ (Loss) from Ordinary activities after Tax (9+10)	(25.98)	11.64	3.58	1.86	41.58
12. Extraordinary Items(Net Of Tax Expenses)	Nil	Nil	Nil	Nil	Nil
13. Net Profit/ (Loss) for the period (11+12)	(25.98)	11.64	3.58	1.86	41.58
14. Share Of Profit/(loss) Of Associates	-NA-	-NA-	-NA-	-NA-	-NA-
15. Minority Interest	-NA-	-NA-	-NA-	-NA-	-NA-
Net Profit/ (Loss) after taxes, Minority Interest and Share Of Profit/(Loss) of Associates (13+14+15)	(25.98)	11.64	3.58	1.86	41.58
17. Paid-up Equity Share Capital (Face Value of Rs.10/- each)	810.00	810.00	810.00	810.00	810.00
18. Reserves excluding revaluation reserves as per balance sheet of previous accounting year	324.27	334.84	293.26	324.27	334.84
19. Earnings Per Share (EPS)					
i. Basic & Diluted before extraordinary items (not annualised)	(0.32)	0.14	0.04	0.02	0.51
ii. Basic & Diluted after extraordinary items (not annualised)	(0.32)	0.14	0.04	0.02	0.51

Trimurthi Drugs & Pharmaceuticals Ltd.

(Signature)
Managing Director

Trimurthi Drugs & Pharmaceuticals Ltd.

4-4-231/1/2 ABC, Inder Bagh, Sultan Bazar,
Hyderabad - 500 095, A.P., India

Tel: 011 2610 7070



TRIMURTHI
GROUP

TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED
CONSOLIDATED AUDITED QUARTERLY RESULTS FOR THE QUARTER ENDED MARCH, 2015

PART-I					
STATEMENT OF CONSOLIDATED AUDITED RESULTS FOR QUARTER IV AND NINE MONTHS ENDED 31/03/2015					
Particulars	3 Months ended 31-03-2015	Preceding 3 months ended 31-12-2014	Corresponding 3 months ended 31-03-2014	Year to date figures for the current period ended 31-03-2015	Year ended 31-03-2014
	Audited	Unaudited	Audited	Audited	Audited
1. Income From Operations					
Net Sales / Income from Operations	100.34	128.65	139.63	511.51	476.06
Other Operating Income	39.98	29.05	13.47	123.45	100.84
Total Operating Income(Net)	140.32	157.70	153.10	634.96	576.90
2. Expenditure					
a. Consumption of Raw Material	Nil	Nil	Nil	Nil	
b. Purchase of Traded Goods	95.64	131.24	98.31	472.24	422.95
c. (Increase)/Decrease in stock in trade and work in Progress	4.32	(20.40)	20.71	(12.80)	1.07
d. Employees Cost	17.18	8.29	14.39	35.86	33.13
e. Depreciation	17.37	8.15	7.18	40.89	28.53
f. Other Expenditure	26.78	8.52	9.34	50.63	28.62
Total	161.28	135.81	149.93	586.82	514.30
Profit/ (Loss) from Operations before Other Income, Finance Cost & Exceptional Items (2-1)	(20.96)	21.89	3.17	48.14	62.60
4. Other Income	(20.63)			(20.63)	1.65
Profit/ (Loss) from Ordinary Activities before Finance Cost & Exceptional Items (3+4)	(41.59)	21.89	3.17	27.51	64.25
6. Finance Cost	0.13	0.11	0.13	0.39	0.64
7. Profit/ (Loss) from Ordinary activities after finance cost but before exceptional items (5+6)	(41.72)	21.78	3.04	27.12	63.61
8. Exceptional Items	Nil	Nil	Nil	Nil	Nil
9. Profit/ (Loss) from Ordinary activities before tax (7+8)	(41.72)	21.78	3.04	27.12	63.61
10. Tax Expense (Including Deferred Tax)	(8.73)	7.27	(0.54)	12.94	20.18
11. Net Profit/ (Loss) from Ordinary activities after Tax (9+10)	(33.00)	14.51	3.58	14.18	43.43
12. Extraordinary Items(Net Of Tax Expenses)	Nil	Nil	Nil	Nil	Nil
13. Net Profit/ (Loss) for the period (11+12)	(33.00)	14.51	3.58	14.18	43.43
14. Share Of Profit/(loss) Of Associates	-NA-	-NA-	-NA-	-NA-	-NA-
15. Minority Interest	(2.26)	1.28	-NA-	5.67	0.76
16. Net Profit/ (Loss) after taxes, Minority Interest and Share Of Profit/(Loss) of Associates (13+14+15)	(30.74)	13.23	3.58	8.51	42.67
17. Paid-up Equity Share Capital (Face Value of Rs.10/- each)	810.00	810.00	810.00	810.00	810.00
18. Reserves excluding revaluation reserves as per balance sheet of previous accounting year	336.82	334.84	293.26	336.82	293.26
19. Earnings Per Share (EPS)					
i. Basic & Diluted before extraordinary items (not annualised)	(0.38)	0.16	0.04	0.11	0.53
ii. Basic & Diluted after extraordinary items (not annualised)	(0.38)	0.16	0.04	0.11	0.53

Managing Director

Trimurthi Drugs & Pharmaceuticals Ltd.

4-4-231/1/2 ABC, Inder Bagh, Sultan Bazar,
Hyderabad - 500 095, A.P., India



TRIMURTHI
GROUP

TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED

CONSOLIDATED AUDITED QUARTERLY RESULTS FOR THE QUARTER ENDED MARCH, 2015

PART-II

Select Information for Quarter IV and Nine Months Ended 31/03/2015

Particulars	3 Months ended 31-03-2015	Preceding 3 months ended 31-12-2014	Corresponding 3 months ended 31-03-2014	Year to date figures for the current period ended 31-03-2015	Year ended 31-03-2014
	Audited	Unaudited	Audited	Audited	Audited
A. Particulars Of Share Holding					
1. Public Share Holding					
- Number of Shares	2849600	3102200	3366200	2849600	3166200
- Percentage of shareholding	35.18%	38.30%	41.56%	35.18%	39.09%
2. Promoters and promoter group shareholding					
a. Pledged / encumbered					
- No of Equity Shares	Nil	Nil	Nil	Nil	Nil
- Percentage of Shares (of the shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil
- Percentage of Shares (of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil
b. Non encumbered					
- No of Equity Shares	5250400	4997800	4733800	5250400	4933800
- Percentage of Shares (of the shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of Shares (of the total share capital of the company)	64.82%	61.70%	58.44%	64.82%	60.91%
Particulars	3 Months Ended (31/03/2015)				
B. Investor Complaints					
Pending at the beginning of the quarter			-NIL-		
Received during the quarter			-NIL-		
Disposed during the quarter			-NIL-		
Remaining unsolved during the quarter			-NIL-		

Segment Reporting

Particulars	Quarters ended			Year Ended	Year ended
	31/03/2015 Audited	31/12/2014 Unaudited	31/03/2014 Audited	31/03/2015 Audited	31/03/2014 Audited
1. Segment Revenue					
a. Pharma Business	109.51	128.65	133.27	520.68	486.39
b. Financial Services	30.81	29.05	19.83	114.28	89.48
c. Investments	(19.67)	0.00	0.00	(19.67)	0.01
d. Trading in Shares	0.00	0.00	0.00	0.00	0.00
Total	120.65	157.70	153.10	615.29	575.88
Less: Inter Segment Revenue	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
Net Sales/ Income From Operations	120.65	157.70	153.10	615.29	575.88
2. Segment Profits (Before tax & Interest From Each Segment)					
a. Pharma Business	(10.70)	7.65	(13.32)	16.82	(19.51)
b. Financial Services	(10.32)	14.13	16.36	31.00	80.44
c. Investments	(20.70)	0.00	0.00	(20.70)	0.01
d. Trading in Shares	0.00	0.00	0.00	0.00	0.00
Total	(41.72)	21.78	3.04	27.12	60.94
Less:					
i. Interest	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
ii. Other Un-allocable expenses net off	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
iii. Un-allocable Income	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
Total Profit Before Tax	(41.72)	21.78	3.04	27.12	60.94
3. Capital Employed					
a. Pharma Business	68.68	127.52	413.38	68.68	413.38
b. Financial Services	940.43	1026.58	681.82	940.43	681.82
c. Investments	113.79	5.00	31.50	113.79	31.50
d. Trading in Shares	0.00	0.00	0.00	0.00	0.00
Total	1122.90	1159.09	1126.70	1122.90	1126.70

For Trimurthi Drugs & Pharmaceuticals Ltd.

Trimurthi Drugs & Pharmaceuticals Ltd.

4-4-231/1/2 ABC, Inder Bagh, Sultan Bazar,
Hyderabad - 500 095, A.P., India

Amund
Managing Director

TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED
CONSOLIDATED ASSETS AND LIABILITIES FOR THE HALF YEAR ENDED ON 31-03-2015



		(Rupees in Lacs)	
Particulars	As at 31/03/2015	As at 31/03/2014	
A. EQUITY AND LIABILITIES			
1. Share Holders' Funds:			
(a) Share Capital	810.00	810.00	
(b) Reserves and Surplus	332.86	336.82	
(c) Money received against warrants			
Sub-Total Share Holders' Funds	1142.86	1146.82	
2. Share Application pending for Allotment	-Nil-	-Nil-	
3. Minority Interest*	27.54	21.87	
4. Non Current Liabilities:			
(a) Long Term Borrowings	-Nil-	1.36	
(b) Deferred Tax Liabilities (Net)	8.32	11.59	
(c) Other Long Term Liabilities	-Nil-	-Nil-	
(d) Long Term Provisions	-Nil-	-Nil-	
Sub-Total Non Current Liabilities	8.32	12.95	
5. Current Liabilities			
(a) Short Term Borrowings	-Nil-	-Nil-	
(b) Trade Payables	47.87	4.53	
(c) Other Current Liabilities	8.47	12.31	
(d) Short Term Provisions	16.26	22.29	
(e) Inter Division	-Nil-	-Nil-	
Sub-Total Current Liabilities	72.59	39.13	
TOTAL EQUITY & LIABILITIES	1251.31	1220.77	
B. ASSETS			
1. Non-Current Assets:			
(a) Fixed Assets	75.28	117.15	
(b) Non-Current Investments	113.78	5.00	
(c) Deferred Tax Assets (Net)	-Nil-	-Nil-	
(d) Long Term Loans and Advances	20.52	20.52	
(e) Other Non-Current Assets	-Nil-	-Nil-	
Sub-Total Non Current Assets	209.58	142.67	
2. Current Assets:			
(a) Current Investments	-Nil-	-Nil-	
(b) Inventories	45.01	32.21	
(c) Trade Receivables	71.53	84.72	
(d) Cash & Cash Equivalents	21.79	132.84	
(e) Short Term Loans and Advances	881.24	806.68	
(f) Other Current Assets	22.16	21.65	
Sub-Total Current Assets	1041.73	1078.10	
TOTAL ASSETS	1251.31	1220.77	

Trimurthi Drugs & Pharmaceuticals Ltd.

4-4-231/1/2 ABC, Inder Bagh, Sultan Bazar,
Hyderabad - 500 095, A.P., India

Tel: 040 2475 7300
W: www.trimurthigroup.com

CIN No: L67120TG1994PLC018950

for Trimurthi Drugs & Pharmaceuticals Ltd.

(Signature)
Managing Director